Last $6.78 USD
Change Today -0.13 / -1.88%
Volume 116.2K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

David P. Bartel Ph.D.

Member of Scientific Advisory Board, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 28 board members in 3 different organizations across 3 different industries.

See Board Relationships
----

Background*

Dr. David P. Bartel, Ph.D. serves as an Associate Professor at Whitehead Institute for Medical Research. Dr. Bartel serves as a Member of Scientific Advisory Board at Alnylam Pharmaceuticals Inc., Firefly BioWorks, Inc. and Regulus Therapeutics Inc. Dr. Bartel, Professor of Biology at MIT, Howard Hughes Medical Institute investigator and member of the Whitehead Institute. Dr. Bartel has made major contributions to recent advances in understanding the role of micro-RNAs ...

Read Full Background

Corporate Headquarters*

3545 John Hopkins Court
San Diego, California 92121

United States

Phone: 858-202-6300
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $6.78 USD -0.13

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$450.0K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.